1Bonadonna RC. Alterations of glucose metabolism in type 2diabetes mellitus [J]. An Overview, 2004, 5 (2): 89-97.
2Kanai Y, Lee WS, You G, et al. The human kidney low affinityNaVglucose co-transporter SGLT2: Delineation of the majorrenal re-absorptive mechanism for D-glucose [J]. J Clin In-vest, 1994, 93(1): 397-404.
3Hediger MA, Coady MJ, Ikeda TS, et al. Expression cloningand cDNA sequencing of the Na+/glucose co-transporter [J].Nature,1987, 330(6146): 379-381.
4Wells RG, Pajor AM, Kanai Y,et al. Cloning of a humankidney cDNA with similarity to the sodium-glucosecotransporter [J]. Am J Physiol, 1992, 263 (3 Pt 2):F459-F465.
5Kaku K, Inoue S,Matsuoka O, et al. Efficacy and safety ofdapagliflozin as a monotherapy for type 2 diabetes mellitus inJapanese patients with inadequate glycaemic control: a phase IImulticentre, randomized, double-blind, placebo-controlled trial[J]. Diabetes Obes Metab,2013, 15 (5): 432-440.
6Obermeier M, Yao M, Khanna A, et al. In vitro characterizationand pharmacokinetics of dapagliflozin, a potent sodium-glucose cotransporter type II inhibitors,in animals and humans[J]. Drug Metab Dispos, 2010, 38 (3):405-414.
7Hardman TC, Dubrey SW. Development and potential role oftype-2 sodium-glucose transporter inhibitors for managementof type 2 diabetes [J]. Diabetes Therapy, 2011,2 ⑶:133-145.
8Fonseca VA,Ferrannini E, Wilding JP, et al. Active- andplacebo-controlled dose-finding study to assess the efficacy,safety, and tolerability of multiple doses of ipragliflozinin patients with type 2 diabetes mellitus [J]. J DiabetesComplications, 2013, 27 (3): 268-273.
9Ferrannini E, Seman L, Seewaldt-Becker E,et al. A Phase lib,randomized, placebo-controlled stndy of the SGLT2 inhibitorempagliflozin in patients with type 2 diabetes [J]. DiabetesObes Metab, 2013, 15 (8): 721-728.
10Miao Z,Nucci G,Amin N, et al. Pharmacokinetics,metabolism, and excretion of the antidiabetic agentertugliflozin (PF-04971729) in healthy male subjectss[J].Drug Metab Dispos, 2013, 41 (2): 445-456.
